RxDoctor Payments Data

Renee Joseph, MD

Internal Medicine · Simpsonville, SCNPI 1528406550

Payments from drug & device makers

$2,680in general payments, 2019–2025

Across 150 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$593
  • Lilly USA, LLC$370
  • Dexcom, Inc.$348
  • Novo Nordisk$326
  • Abbott$178
  • Amgen$112
  • plus $752 from 22 others

What the payments were for

  • Food & beverage$2,680100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,680 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$125,451
Medicare patients
285
Services billed
2,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide174$246,129
MounjaroTirzepatide46$63,154
JardianceEmpagliflozin65$58,358
RybelsusSemaglutide25$39,516
EliquisApixaban21$24,819
Janumet XrSitagliptin Phos/Metformin Hcl18$24,735
JanuviaSitagliptin Phosphate16$21,028
PremarinEstrogens, Conjugated14$5,576
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,739
Atorvastatin Calcium482$4,411
Albuterol Sulfate HfaAlbuterol Sulfate125$3,546
SymbicortBudesonide/Formoterol Fumarate16$3,452
SynthroidLevothyroxine Sodium35$3,246
Novolog FlexpenInsulin Aspart12$3,093
Gabapentin168$2,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$326$285,645199 claims
Lilly USA, LLCMounjaro$370$63,15446 claims
Boehringer IngelheimJardiance$16$58,35865 claims
MerckJanumet Xr, Januvia$11$45,76334 claims
PfizerEliquis, Premarin$49$30,39535 claims
AstraZenecaSymbicort$28$3,45216 claims
AbbVieSynthroid$593$3,24635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Simpsonville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →